A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).

Trial Details

NCT ID
NCT06881992
Phase
PHASE3
Sponsor
Rezolute
Status
RECRUITING
Cancer Type
Pancreatic Neuroendocrine Pancreatic Cancer
Interventions
  • Ersodetug
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Bethesda, Maryland, United States|38.98067,-77.10026
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist
  • Male or female participants of ≥18 years of age who provide written informed consent.
  • Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriatel…
  • Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administrat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Neuroendocrine Pancreatic Cancer Trials on Trialify →